Efficient osteoclast differentiation requires local complement activation
- 25 November 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (22) , 4456-4463
- https://doi.org/10.1182/blood-2010-01-263590
Abstract
Previous studies using blocking antibodies suggested that bone marrow (BM)–derived C3 is required for efficient osteoclast (OC) differentiation, and that C3 receptors are involved in this process. However, the detailed underlying mechanism and the possible involvement of other complement receptors remain unclear. In this report, we found that C3−/− BM cells exhibited lower RANKL/OPG expression ratios, produced smaller amounts of macrophage colony-stimulating factor and interleukin-6 (IL-6), and generated significantly fewer OCs than wild-type (WT) BM cells. During differentiation, in addition to C3, WT BM cells locally produced all other complement components required to activate C3 and to generate C3a/C5a through the alter-native pathway, which is required for efficient OC differentiation. Abrogating C3aR/C5aR activity either genetically or pharmaceutically suppressed OC generation, while stimulating WT or C3−/− BM cells with exogenous C3a and/or C5a augmented OC differentiation. Furthermore, supplementation with IL-6 rescued OC generation from C3−/− BM cells, and neutralizing antibodies to IL-6 abolished the stimulatory effects of C3a/C5a on OC differentiation. These data indicate that during OC differentiation, BM cells locally produce components, which are activated through the alternative pathway to regulate OC differentiation. In addition to C3 receptors, C3aR/C5aR also regulate OC differentiation, at least in part, by modulating local IL-6 production.Keywords
This publication has 43 references indexed in Scilit:
- A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritisThe Journal of Experimental Medicine, 2007
- Decay-accelerating factor modulates induction of T cell immunityThe Journal of Experimental Medicine, 2005
- Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factorBone, 1999
- Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal CellsEndocrinology, 1998
- Molecular Cloning and Characterization of the Human Anaphylatoxin C3a ReceptorPublished by Elsevier ,1996
- Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors.Journal of Clinical Investigation, 1993
- Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6Science, 1992
- The specific production of the third component of complement by osteoblastic cells treated with 1α,25‐dihydroxyvitamin D3FEBS Letters, 1991
- Structure and function of the anaphylatoxinsSpringer Seminars in Immunopathology, 1984
- Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyteThe Journal of Experimental Medicine, 1980